 - history of other malignancy within two years prior to screening, except for prostate cancer T1c, T2ab with definitive treatment, prostate-specific antigen PSA 1 ngml, and without ongoing hormone suppression or adequately treated in situ carcinoma of the cervix, basal cell carcinoma, or squamous cell carcinoma of the skin 